[go: up one dir, main page]

NZ765884B2 - Pi4kiiibeta inhibitors - Google Patents

Pi4kiiibeta inhibitors Download PDF

Info

Publication number
NZ765884B2
NZ765884B2 NZ765884A NZ76588419A NZ765884B2 NZ 765884 B2 NZ765884 B2 NZ 765884B2 NZ 765884 A NZ765884 A NZ 765884A NZ 76588419 A NZ76588419 A NZ 76588419A NZ 765884 B2 NZ765884 B2 NZ 765884B2
Authority
NZ
New Zealand
Prior art keywords
acceptable salt
pharmaceutically acceptable
compound
exemplified
viral infection
Prior art date
Application number
NZ765884A
Other versions
NZ765884A (en
Inventor
Nicholas Paul Barton
Sophie Marie Bertrand
Kenneth Down
Matthew Gray
Original Assignee
Glaxosmithkline Intellectual Property Development Limited
Filing date
Publication date
Priority claimed from GBGB1800734.4A external-priority patent/GB201800734D0/en
Priority claimed from GBGB1817616.4A external-priority patent/GB201817616D0/en
Application filed by Glaxosmithkline Intellectual Property Development Limited filed Critical Glaxosmithkline Intellectual Property Development Limited
Priority claimed from PCT/EP2019/050983 external-priority patent/WO2019141694A1/en
Publication of NZ765884A publication Critical patent/NZ765884A/en
Publication of NZ765884B2 publication Critical patent/NZ765884B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention relates to compounds of formula (I) which are inhibitors of kinase activity, pharmaceutical formulations containing the compounds and their uses in treating and preventing viral infections and disorders caused or exacerbated by the viral infection wherein R1, R2, R3, R4a, R4b, R4c, R5, W, X, Y and Z are defined herein.

Claims (8)

1. A nd which is (S)-N-(1-hydroxypropanyl)(5-(2-hydroxypropanyl) methyl((3-(1-methyl-1H-imidazolyl)benzyl)amino)pyrazolo[1,5-a]pyrimidinyl)- N,2-dimethylbenzamide (Compound 22) or a pharmaceutically acceptable salt thereof.
2. Use of the compound defined in claim 1 or a pharmaceutically acceptable salt in the manufacture of a medicament for the treatment of a viral infection.
3. Use of the compound defined in claim 1 or a pharmaceutically acceptable salt in the cture of a medicament for the treatment of a disorder caused or exacerbated by a viral infection.
4. The use of the compound defined in claim 1 or a pharmaceutically acceptable salt thereof according to claim 3, wherein the disorder is COPD.
5. A pharmaceutical ation comprising the compound d in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically able ent.
6. A compound according to claim 1, substantially as herein described or exemplified.
7. A use according to claim 2, substantially as herein described or exemplified.
8. A pharmaceutical formulation according to claim 5, substantially as herein described or exemplified.
NZ765884A 2019-01-15 Pi4kiiibeta inhibitors NZ765884B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1800734.4A GB201800734D0 (en) 2018-01-17 2018-01-17 Novel compounds
GBGB1817616.4A GB201817616D0 (en) 2018-10-29 2018-10-29 Novel compounds
PCT/EP2019/050983 WO2019141694A1 (en) 2018-01-17 2019-01-15 Pi4kiiibeta inhibitors

Publications (2)

Publication Number Publication Date
NZ765884A NZ765884A (en) 2024-10-25
NZ765884B2 true NZ765884B2 (en) 2025-01-28

Family

ID=

Similar Documents

Publication Publication Date Title
PH12022552828A1 (en) Substituted aminothiazoles as dgkzeta inhibitors for immune activation
PH12021500049A1 (en) 2,3-dihydroquinazolin compounds as nav1.8 inhibitors
NZ604345A (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
MX2008013836A (en) 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
SI3106463T1 (en) Substituted pyrazolo(1,5-)pyrimidine compounds as trk kinase inhibitors
EP4467549A3 (en) Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
WO2007085833A3 (en) Pyrimidine derivatives
IL159843A0 (en) Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2007042786A3 (en) 4 -heteroaryl pyrimidine derivatives and use thereof as protein kinase inhibitors
TNSN06411A1 (en) Pyrimidine urea derivatives as kinase inhibitors
WO2005028479A3 (en) Hiv replication inhibiting purine derivatives
NZ582089A (en) Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir
PH12021550687A1 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
PH12022551226A1 (en) Pyrrolotriazine compounds acting as mnk inhibitor
JOP20210338A1 (en) Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide
TN2012000132A1 (en) N-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
MX2023010087A (en) Heterocyclic derivatives as janus kinase inhibitors.
MX2023006842A (en) Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof.
WO2021232067A8 (en) Stat3 inhibition for treatment and prevention of human coronavirus infection
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
IL276013B1 (en) Pi4kiiibeta inhibitors
WO2007113243A3 (en) Use of pde 5 inhibitors for the treatment of overactive bladder
MX2023010083A (en) Heterocyclic derivatives as janus kinase inhibitors.